Study Design and Participants
HYPERTENSIVE EMERGENCY, RECRUITMENT, SECONDARY HYPERTENSION, ESSENTIAL HYPERTENSION
This prospective, randomized, controlled clinical trial was conducted at the Renmin Hospital of Wuhan University between September and October 2022 and followed up on April 2023.The recruitment continued until the end of October 2022, and the planned sample size was achieved. The inclusion criteria were as follows: (1) age 20-80 years, (2) first diagnosis of essential hypertension (BP measured at home 3 times on different days; systolic blood pressure [SBP] >140 mm Hg or diastolic blood pressure [DBP] >90 mm Hg), (3) received no antihypertensive medications before enrollment, (4) used smartphones every day, and (5) considered appropriate to undergo lifestyle modification for 6 months. Patients with suspected secondary hypertension or hypertensive emergency were excluded. 